Altimmune announces oral presentation of pemvidutide clinical data at upcoming nash-tag conference on january 7, 2023

Gaithersburg, md., jan. 04, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that dr. stephen a. harrison, chairman and co-founder, pinnacle clinical research and summit clinical research, will deliver an oral presentation of the results of altimmune's recently completed 12-week phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (nafld) at the nash-tag conference, which will be held in park city, ut on january 6-7, 2023. pemvidutide is a novel, investigational, peptide-based glp-1/glucagon dual receptor agonist in development for the treatment of obesity and nash. details for the oral presentation are as follows:
ALT Ratings Summary
ALT Quant Ranking